I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know is no longer part of the deal here but what does everyone think about the drag racing kid's motor? Is it really a breakthrough (as in 110 mpg with good power) or a hype/scam? I never bought RVGD because I generally don't trust partnerships in penny stocks but like following innovation as a curiosity.
How about, "AGM will never happen", "You will not see an Islechem report", "the LOI for 45 sites will never turn into a contract" and then there is the posting of old information without any date obviously trying to infer that it is hot off the wire news which would look unfavorable. It happens on both sides.
Even some of us longs get those types of PM's and we cannot stop "the crew" and they cannot see how much harm they are doing to the stock. It is a huge turn-off for anyone who is new and has an actual interest in the stock and asks honest questions. I wish it were different and have tried to change it but I can only do so much. Try to separate "the crew" from the stock as they may have actually found a long-term, high growth company in it's infancy. Also "the crew" often speculates overly optimistically on the timing of events and yet "the anti-crew" seems to enjoy twisting the facts to make things look considerably worse than they actually are. JMHO
I am trying to help you understand that IPO has a very specific meaning and it would be better not to use it incorrectly. The key word is "public" and the way JBI became public is through a reverse-merger not an IPO and before the reverse-merger the general public could not invest into the former company because it was never publicly traded or quoted on any exchange.
I don't think I can explain it any further so please don't reply. There are plenty of investor websites if you need more clarity.
If I stated on this message board that my IQ was higher than JohnB (174), I would think that I would be smart enough to read a definition and understand it before continuing to post misinformation without deferring to someone else using it improperly, but then that is just me.
IPO = Initial Public Offering - when you use stock market term incorrectly it is confusing.
JBII never had an IPO but instead did a reverse merger to become "publicly" traded.
http://www.investopedia.com/terms/i/ipo.asp
The price quote in the body of the article is inaccurate as it was not MSB on the Australian exchange as it was quoted to be.
The US ADR for Mesoblast is MBLTY
Making Sense Of Stem Cell Investments: An Update
By: Jim Nelson Thursday, May 13, 2010 12:18 PM
http://www.istockanalyst.com/article/viewarticle/articleid/4118125
The pace at which some of the world's latest technological advances are emerging is incredible. But while most investors wait until advances become commonplace before getting a piece of the action, keeping ahead of the game can lead to mind blowing profits. To that end, I want to tell you about the latest advances in stem cell therapies – and a look at a company that's making them happen Down Under…
Have you ever wondered why it takes longer to recover from a strenuous workout or a muscle injury than it did when you were younger? As our knowledge of molecular cell repair machinery improves, we expect therapies that will restore different tissue types to a more youthful state.
For example, in September, scientists at the Children's Hospital of Pittsburgh identified a group of stem cells taken from blood vessels that could be used to treat damaged heart tissue and rebuild muscle damage caused by diseases such as muscular dystrophy. In fact, these adult stem cells, known as myoendothelial cells, can not only be differentiated into muscle tissue, but bone and cartilage as well. These myoendothelial cells are much more efficient for creating new muscle than other adult stem cell types that can be taken from patients.
Muscle regeneration is particularly important when it comes to heart muscle. Heart attacks often destroy heart muscle, and there are currently no commercial options for regrowing it. However, Harvard Stem Cell Institute and Massachusetts General Hospital scientists were able to use stem cells to regrow functioning heart muscle in mice. The plan is to use these stem cell techniques to regrow heart muscle in patients that have had heart attacks.
An Australian company is doing just that. In Stage II clinical trials in the United States, Mesoblast Ltd. (ASX: MSB: 18.83, -0.89) showed that its stem cell-based therapy, Revascor, showed sustained improvement in heart muscle function six months after patients received the minimal dose of the drug in a single injection. Ultimately, more-powerful pluripotent stem cells will do the same thing even more efficiently, but this product could come to market first. The company is currently presenting its findings at the American Heart Association annual conference.
Researchers at the Northwestern University Feinberg School of Medicine have also been trying to repair damaged hearts through stem cell therapies. In a double-blind placebo-controlled study, they transplanted adult stem cells into patients with severe angina and heart disease. The results were astonishing: Patients that had received the stem cell treatment doubled the amount of time they were able to walk without feeling pain, and overall experienced less pain over the course of the day.
The stem cell therapy caused new blood vessels to grow in the heart tissue, supplying the muscle with a more adequate blood supply.
Also, University of California researchers have found some of the molecular triggers that lead to aging in muscle tissue. Researchers took biopsies from the quadriceps of the participant's muscle at the beginning of the study and then immobilized it in a cast for two weeks. Immobilized muscle tends to atrophy. After removing the casts, the participants went through an exercise regimen to restore the lost muscle mass and further biopsies were taken.
They found that the actual number of adult stem cells responsible for tissue regeneration is halved in old muscle compared with young muscle. They also found that younger participants had four times more regenerative cells working at repairing the muscle compared with older subjects in the study. They knew from previous studies that there are biochemical signals that tell stem cells where to go to repair muscle tissue and that these signals decline as part of aging.
The molecular receptor on the adult stem cells, called Notch, causes growth when it is activated. These cells also have a molecular receptor for the TGF-beta protein that reduces the stem cell's ability to divide when it is excessively activated. Past studies in mice revealed that aging causes a decline in the Notch receptor and an increase in the amount of TGF-beta. This state causes a decline in the ability of the stem cells to rebuild tissue.
The latest study showed that these pathways found in mice are also present in humans. However, this study also showed for the first time the importance of another biochemical regulator of the activity of the Notch receptor. Known as MAPK, this enzyme is well-known for its function in forming organs in a wide variety of animals, from worms to insects and mammals and now to humans. The researchers discovered that when they raised old human muscle in a culture and forced the activation of this enzyme, the ability of the muscle to regenerate was improved. This is a technology with enormous financial promise.
I'll fill you in when more of these emergent stem cell technologies become investable.
For transformational profits,
Patrick Cox
Penny Sleuth
May 13, 2010
You bring up a valid concern and if nothing new happens before July, I have no doubt that the stock will suffer even if the pipe shareholders were to hold (based on perception). I have no doubt that JB also knows this which will put tremendous pressure on JB to show progress in the next 7 weeks:)
It is a risk, but I believe that we will hear about uplisting before then. If uplisting is rejected, it will hurt the stock price for the short term no doubt. However, long-term the value of P2O will decide the stock price value. If uplisting is successful and URS reports before the restrictions end then the stock could be at a much higher level with more volume minimizing the impact.
If you do not believe JB, then there is no point in any discussion of the stock but if you believe JB, then you understand that he has stated that there is an order of events and right now uplisting is the next event and it is not in JB's control and he must be very careful what he says while the uplisting process is taking it's course.
I believe when the media plan was unveiled that JB expected the uplisting to have already occurred beforehand. The plan with the media roll out will happen when the time is right and I am glad that they are getting all of their ducks in a row and not trying to force anything before it is ready for prime time.
For someone who admittedly wants to "flip" JBII stock, I can see how this would be very frustrating.
To my knowledge JB never said "Mutual Funds" as you are trying to twist his words to imply. You can have your own opinion as to the benefit that these funds bring to JBII but to deny that they exist causes me to question your DD skills.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49517947
LYNDA A. Gorby
http://www.spencerinternational.com/new/spencerinternational/content.asp?contentid=2017301494
I guess we are the only two boardmarks here? I can't post it onto the premium boards could you please do that for me?
Making Sense Of Stem Cell Investments: An Update
By: Jim Nelson Thursday, May 13, 2010 12:18 PM
http://www.istockanalyst.com/article/viewarticle/articleid/4118125
The pace at which some of the world's latest technological advances are emerging is incredible. But while most investors wait until advances become commonplace before getting a piece of the action, keeping ahead of the game can lead to mind blowing profits. To that end, I want to tell you about the latest advances in stem cell therapies – and a look at a company that's making them happen Down Under…
Have you ever wondered why it takes longer to recover from a strenuous workout or a muscle injury than it did when you were younger? As our knowledge of molecular cell repair machinery improves, we expect therapies that will restore different tissue types to a more youthful state.
For example, in September, scientists at the Children's Hospital of Pittsburgh identified a group of stem cells taken from blood vessels that could be used to treat damaged heart tissue and rebuild muscle damage caused by diseases such as muscular dystrophy. In fact, these adult stem cells, known as myoendothelial cells, can not only be differentiated into muscle tissue, but bone and cartilage as well. These myoendothelial cells are much more efficient for creating new muscle than other adult stem cell types that can be taken from patients.
Muscle regeneration is particularly important when it comes to heart muscle. Heart attacks often destroy heart muscle, and there are currently no commercial options for regrowing it. However, Harvard Stem Cell Institute and Massachusetts General Hospital scientists were able to use stem cells to regrow functioning heart muscle in mice. The plan is to use these stem cell techniques to regrow heart muscle in patients that have had heart attacks.
An Australian company is doing just that. In Stage II clinical trials in the United States, Mesoblast Ltd. (ASX: MSB: 18.83, -0.89) showed that its stem cell-based therapy, Revascor, showed sustained improvement in heart muscle function six months after patients received the minimal dose of the drug in a single injection. Ultimately, more-powerful pluripotent stem cells will do the same thing even more efficiently, but this product could come to market first. The company is currently presenting its findings at the American Heart Association annual conference.
Researchers at the Northwestern University Feinberg School of Medicine have also been trying to repair damaged hearts through stem cell therapies. In a double-blind placebo-controlled study, they transplanted adult stem cells into patients with severe angina and heart disease. The results were astonishing: Patients that had received the stem cell treatment doubled the amount of time they were able to walk without feeling pain, and overall experienced less pain over the course of the day.
The stem cell therapy caused new blood vessels to grow in the heart tissue, supplying the muscle with a more adequate blood supply.
Also, University of California researchers have found some of the molecular triggers that lead to aging in muscle tissue. Researchers took biopsies from the quadriceps of the participant's muscle at the beginning of the study and then immobilized it in a cast for two weeks. Immobilized muscle tends to atrophy. After removing the casts, the participants went through an exercise regimen to restore the lost muscle mass and further biopsies were taken.
They found that the actual number of adult stem cells responsible for tissue regeneration is halved in old muscle compared with young muscle. They also found that younger participants had four times more regenerative cells working at repairing the muscle compared with older subjects in the study. They knew from previous studies that there are biochemical signals that tell stem cells where to go to repair muscle tissue and that these signals decline as part of aging.
The molecular receptor on the adult stem cells, called Notch, causes growth when it is activated. These cells also have a molecular receptor for the TGF-beta protein that reduces the stem cell's ability to divide when it is excessively activated. Past studies in mice revealed that aging causes a decline in the Notch receptor and an increase in the amount of TGF-beta. This state causes a decline in the ability of the stem cells to rebuild tissue.
The latest study showed that these pathways found in mice are also present in humans. However, this study also showed for the first time the importance of another biochemical regulator of the activity of the Notch receptor. Known as MAPK, this enzyme is well-known for its function in forming organs in a wide variety of animals, from worms to insects and mammals and now to humans. The researchers discovered that when they raised old human muscle in a culture and forced the activation of this enzyme, the ability of the muscle to regenerate was improved. This is a technology with enormous financial promise.
I'll fill you in when more of these emergent stem cell technologies become investable.
For transformational profits,
Patrick Cox
Penny Sleuth
May 13, 2010
You must admit that with all the market turmoil the stock has held over $4 quite well and if we do get a NASDAQ uplisting then it could be quite a chase if you are not already invested. I happen to think that JB wants to be a hero in his home town with many friends and family invested but that can only happen if P2O is a home run success and I do not plan on being on the sidelines when he hits it out of the park.
It does not take much to read between the lines and perceive what is really going on here. I doubt if my IQ is 170 (never tested it though) but it seems apparent to me that JB is between a rock and a hard place until the uplisting decision is made. It would not be smart to put out a bunch of updates and change accountants or auditors while in the process of being under review by NASDAQ. JB has no control over the timing and so I believe his lips are sealed until we learn about the uplisting. I think that progress is being made that will become known after the uplisting decision (and that would be true for a NASDAQ or AMEX upgrade). That being said the late form "D" should not have happened and after the uplisting decision heads should roll in that department because if they are not serious about their filings, then there is no point in even uplisting. Please note that I am not blaming JB for the late filing but thoses responsible need to stay on top of the filings and understand that it is a very big deal.
Well, it might make some people feel better if they tried to look at buying ITRO to being similar to making a donation to the Sierra Club, Greenpeace or another ecological organization and don't think about it or watch the daily price and possibly one day you will get your brokerage statement and realize that you hit the lottery. Green is good.
You need to do a reverse merger with this guy (oh yea, someone tried that and it did not work out for those sharholders). Another little guy doing what the big billion dollar auto makers cannot do?
http://www.hp2g.com/articles.html
I guess he was not impressed by the EEStor demo? If insiders start selling then you will know for sure that this is toast.
Rumors like this are started to drive down the price. I agree that an RS should be considered when the time is right and it needs to be properly presented and make sure the stock climbs an upward path for the week following. The AS must also be reduced with a 3-1 ratio so as not to send the wrong signal (for every share that is 1000 RS'ed the AS is reduced 3000 shares). With the current share structure and liquidity ITRO will not attract high net worth investors so RS makes sense if done correctly. Maybe after phase one is complete and a PR stating that ITRO is cash flow positive and paying down it's debt without further dilution and DR Whitney along with several other managers are buying stock on the open market because they believe it is very undervalued. ITRO needs to also state that they have never done an R/S before in the companies (15?) year history and that it is being done for the benefit of the shareholders.
Of course another option is for the company to buy back shares on the cheap.
The company can accept or reject funding from whoever it wants at it's discretion. I asked about the pipe and I was not given a chance to buy into it either and I doubt that I ruffle as many feathers on this board as much as some others. No one can keep you from buying shares on the market and no one can keep you from joining John's facebook and asking him your questions (as long as you provide a real name you will be accepted).
In answer to your question lowman - Put a CTGI chart up against JBII. It has done that and more and if they can continue to execute they will go much, much higher from here IMHO.
I guess the real question would be who would buy $4 million dollars of JBII stock (even at a discount) if they did not believe that they would be worth a lot more later?
WOW - MUST READ THIS - I guess this settles the percentage ownership of Angioblast... :)
MESOBLAST TO ACQUIRE ANGIOBLAST SYSTEMS INC
Mesoblast Successfully Completes Capital Raise
Key Points:
* Mesoblast acquires all remaining shares of its USA associate company, Angioblast Systems Inc
via a share exchange offer.
* Acquisition accompanied by capital raising of $37 million from new and existing international and domestic investors
* Mesoblast Group will have full commercial and intellectual property rights to entire Mesenchymal Precursor Cell (MPC) technology platform
* Product pipeline set to broaden beyond orthopaedic applications, to include full ownership of products for potentially lucrative applications such as congestive heart failure, heart attack, eye disease, diabetes and bone marrow transplantation
* Mesoblast Group will present strengthened commercial partnering capability
* Professor Silviu Itescu appointed CEO and Managing Director of Mesoblast Group
* Strengthened and streamlined global leadership team
* New Mesoblast Group will have a combined capitalisation at the closing share price on May 3 2010 of approximately $455 million, not including the current placement
* EGM to be held for Mesoblast shareholders to ratify acquisition and capital raising
Melbourne, Australia; 12 May 2010: Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB;ADR:MBLTY), today announced that it will acquire its United States associate company, Angioblast Systems, Inc. (Angioblast). Additionally, Mesoblast announced it has completed a capital raising of $37 million to fund the acquisition and advance operations of the expanded Mesoblast Group. These funds comprise $24 million invested immediately and $13 million committed subject to both shareholder approval and completion of the acquisition offer.
Mesoblast Chairman Brian Jamieson said: “We are delighted to bring the commercial rights to the patented adult stem cell technology platform under one umbrella. With Mesoblast moving to 100% ownership of Angioblast, Mesoblast shareholders will derive much greater potential benefit from product commercialisation, and from the broader strategic partnerships or collaborations Mesoblast will now be able to conclude.”
The capital was raised from United Kingdom institutional and sophisticated investors, as well as from new and existing Australian investors, at a share price of $1.70, representing a 12% discount to the Company’s closing price on May 3 2010. The placement was managed by Southern Cross Equities to international investors and in conjunction with Lodge Partners to domestic investors. The acquisition has been structured on an agreed exchange ratio of Mesoblast shares for Angioblast stock. To acquire the remaining fully-diluted Angioblast stock which is not already owned by Mesoblast (approximately 67%), the Company proposes to issue an additional 94.6 million Mesoblast shares to Angioblast security holders. Together with Mesoblast’s current 140.6 million shares on issue, post-acquisition the Mesoblast Group will have a total of up to 235.2 million shares outstanding.
Angioblast stockholders will be given the election to take the acquisition consideration either as 100% Mesoblast fully paid ordinary shares or up to 15% in cash and the balance (a minimum of 85%) in Mesoblast fully paid ordinary shares. The cash component will enable Angioblast stockholders who are subject to United States federal tax to fund the payment of capital gains tax arising as a result of this transaction.
The acquisition is subject to various conditions including Mesoblast and Angioblast shareholder approvals and satisfactory due diligence. An Extraordinary General Meeting of Mesoblast shareholders to ratify the acquisition is expected to be held before the end of June 2010, with all shareholders receiving full documentation prior to this date.
At the Mesoblast share price as at the close of trading on May 3 2010, this would result in a capitalisation of Mesoblast (not including the capital raising as referred to in this announcement) of $455 million.
Mr Jamieson also announced the appointment of Mesoblast’s current Executive Director, Professor Silviu Itescu, as Chief Executive Officer and Managing Director of the Group, Mesoblast Limited. The appointment takes effect immediately.
“The appointment of Professor Itescu as the leader of the Group will ensure that Mesoblast continues to deliver on shareholder value.
“As a leader in the global stem cell space, he brings enormous international knowledge of the regenerative medicine industry, combined with experienced and formidable business acumen,” Mr Jamieson said.
Professor Itescu said that the Angioblast acquisition would enable the Mesoblast Group to significantly broaden its product portfolio based on 100% ownership of the intellectual property underpinning the company’s patented adult stem cell technology platform. “Transforming Mesoblast from a biologics company focused on orthopaedic applications to a global leader in the broader regenerative medicine industry should prove to be a pivotal event in the Company’s evolution,” he said.
“By consolidating our technology platform and assets into one company we will be able to both streamline our corporate operations and strengthen the global leadership team as the Company moves to the next level of its corporate maturity. Additionally, we will now be able to rationally deploy all of our available resources according to where we deem to have the greatest commercial opportunities.
“Mesoblast is now a mature multi-product company with products in late, mid, and early stage development. The Company’s product pipeline will be significantly extended beyond its orthopaedic focus, including spinal fusion and osteoarthritis, to include products for treating diverse conditions such as congestive heart failure, heart attacks, eye diseases, diabetes, and bone marrow repair.
“This breadth of products will enable the Mesoblast Group to focus on three simultaneous commercial strategies: taking lead products to market on our own and retaining 100% of the commercial upside, entering into distribution agreements to leverage sales/marketing strength, and partnering through broad-based strategic alliances,” Professor Itescu added.
About Mesoblast
Mesoblast Limited (ASX:MSB;ADR:MBLTY) has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com
Ok experts - Is this NSS story for real?
http://www.deepcapture.com/wp-content/uploads/2009/10/story-of-dendreon.pdf
Not completely "Naked" shorting but I thought it was interesting as illegal manipulation of the rules.
http://pipes.dealflowmedia.com/wires/article.cfm?title=SEC-Charges-Two-Individuals-Short-Selling-Ahead-Offerings&id=ylsttodvndbxdbw
I agree, another wheel not reinvented - lol
Lighting Science Group Introduces 'Factor 4'
Date : 05/11/2010 @ 11:54AM
Source : PR Newswire
Stock : Lighting Science Group Corp (OTC) (LSCG)
Quote : 1.17 0.0 (0.00%) @ 4:19PM
Lighting Science Group Introduces 'Factor 4'
The First Commercial LED Form Factor To Reach Price And Output Parity With Conventional HID Lighting At A Quarter Of The Size And Weight While Consuming Less Than A Quarter Of The Energy
PR Newswire
SATELLITE BEACH, Fla., May 11 /PRNewswire-FirstCall/ --
Continuing its campaign to democratize ultra-efficient LED lighting, Lighting Science Group will unveil at LightFair International 2010 an affordable breakthrough in commercial lighting technology -- Factor 4. Built in the USA, the highly efficient 7x7x3 inch form factor is a quarter of the size and weight (8 lbs.) of conventional lighting products. Truly a breakthrough in sustainable lighting design, the Factor 4 luminaire is 75% more efficient than conventional lighting technology while providing equivalent light output. Furthermore, with optional built-in WiFi/mesh network capability, Factor 4 luminaires can be constantly monitored and controlled using a central network -- saving maintenance time and energy cost. Today's announcement comes on the heels of the Lighting Science Group's successful launch of a breakthrough line of high quality, affordable retrofit LED lamps with a suggested retail price starting below $20.
"We believe that the Factor 4 luminaire sets a new standard for high-performance and sustainable lighting that Americans can afford," said Zach Gibler, Chief Executive Officer, Lighting Science Group. "The ultra-efficient, yet compact, Factor 4 luminaire has the potential to save Americans hundreds of dollars in maintenance, replacement, and energy costs. At Lighting Science Group, we are continuing to push the boundaries of what is possible using LED technology to bring to market high quality, yet affordable, lighting solutions."
To ensure performance and reliability, the Factor 4 luminaire will be tested by an independent laboratory approved by the U.S. Department of Energy's CALiPER program. Factor 4 luminaires will be available in the second half of 2010 through lighting distributors and directly from Lighting Science Group. To see the new Lighting Science Factor 4 luminaire, visit booth # 2335 at LightFair International 2010, May 12-14 in Las Vegas, Nevada.
About Lighting Science
Lighting Science Group Corporation (Pink Sheets: LSCG) designs, develops, manufactures and markets LED lighting solutions that are environmentally friendlier and more energy efficient than traditional lighting products. LSG offers retrofit LED lamps in form factors that match the form factor of traditional lamps or bulbs and LED luminaires for a range of applications including public and private infrastructure for both indoor and outdoor applications. LSG's Custom Solutions business unit designs, develops and manufactures custom LED lighting solutions for architectural and artistic projects. LSG is headquartered in Satellite Beach, Florida; LSG's Custom Solutions business unit is based in Rancho Cordova, California; LSG's European operations are based in Goes, The Netherlands; and, LSG has sales offices in Tokyo, Japan, Buckinghamshire, England and Sydney, Australia. LSG has over 200 workers in its Satellite Beach, Florida manufacturing facility building lighting products from domestic and imported parts. LSG is a Pegasus Capital Advisors portfolio company. More information about LSG is available at www.lsgc.com.
Be sure to visit Lighting Science Group at LightFair International 2010 -- Booth # 2335
Forward Looking Statements Certain statements in this press release may constitute "forward-looking statements" made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The statements include, but are not limited to statements regarding the performance of LSG and the performance of LSG's products using terminology such as "development," "well positioned," "leading," "breakthrough," "advance," "success," "will," "should," "expected," "best in class," "unparalleled," "would," "could," "expect," "intend," "plan," "anticipate," "believe," "potential," "opportunity," "greater," "preparing," "excellent" or "extensive." Such statements reflect the current view of LSG with respect to future events and are subject to certain risks, uncertainties and assumptions. Known and unknown risks, uncertainties and other factors could cause actual results to differ materially from those contemplated by the statements. In evaluating these statements, you should specifically consider various factors that may cause our actual results to differ materially from any forward-looking statements. Readers should carefully review the risk factors detailed under "Risk Factors" in our Form 10-K's, Form 10-Q's and other Securities
and Exchange Commission filings.
SOURCE Lighting Science Group Corporation
The Royal Bank of Scotland (RBS) report:
http://www.mesoblast.com/investor/RBS%20-%20MSB%2026%20FEBRUARY%202010.pdf
How about removing the "sticky" on the loan that we already got and putting your video post as sticky?
http://www.rasertech.com/media/videos/hhi-tours-raser
Every potential investor needs to see that video.
To kill all viruses or not to kill all viruses... That becomes an interesting question:
http://www.discoverymedicine.com/Aravind-Asokan/2010/04/29/reengineered-aav-vectors-old-dog-new-tricks/
I disagree, they should have worked with Canon to find a compromise that would have allowed Toshiba to make the TV's and get a reasonably higher royalty. Then every flat screen maker would have had to come to us on our terms or else give up on the flat screen market. We can argue about it all we want but the stock has never recovered since the deal with Canon fell apart. On another note the future is looking good here. I hope the military likes our nano's.
I would have to go back and check it but as I recall they sued Canon because of the Canon/Toshiba deal and the end results were that the whole contract was canceled and I did not get my SED TV. It would have really put us on the map many years ago. After lawyers fees and time lost anything they got did not keep the stock over the $2 it was trading at the time = bad deal for stock holders - IMHO
That brings up a sore subject in case you are not aware of the Canon deal that went south a few years back. Not this companies finest hour. They are much more diversified now and seem to be on track and hopefully have learned their lesson.
I think you will find more realistic short data here:
http://www.shortsqueeze.com/?symbol=jbii&submit=Short+Quote%E2%84%A2
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=jbii#getShortInfo
http://failstodeliver.com/
My understanding is that the FINRA data also includes buys that have not settled but are not necessarily short.
Great Post on Plastic recycling misconceptions. Everyone should read it.
I have no doubt that you are correct when looking at a technically efficient competitor. But the point I was getting to is that if you believe that "Plastic To Oil" is a viable business with hugh economic rewards and you want to invest, then what options do you have to chose from? That is what I was using as the starting basis for a comparison from my original comment when I correct my error stating that JBII was the only publicly traded P2O company.
So our closest competitor announced on Oct 31, 2008 a contract to build a P2O in Thailand which was finally announced as completed on April 04, 2010? A year an a half to build one site? Do you know how much it cost to build? Do you know how much land it takes for the facility? Do you know how much labor it takes to run it? Do you know how much oil/fuel it produces per day? Does it provide the fuel to run the plant? These are things that need to be known to make a real comparison. JBII has been prodded and poked for every little detail while other companies are brought forth as a comparison, yet none of their details are known. It does not make sense to claim P2O is not viable and then point to the competition.
Oh yes, forgive me as I did forget that I also looked into NTIC a while back and you are right as they are publicly traded and have a P2O division. They are also several companies and their P2O division seems to have been on the back burner for a couple of years now...
6 months (per 4/28/2010 announcement)
http://ih.advfn.com/p.php?pid=nmona&article=42565510&symbol=NY^RZ
fed - maybe you should fly to Reno and sign an NDA and then tell us whatever you can legally tell us. $holdier Hard is a great board mod but he is not obligated to answer any questions and he does not make the stock go up or down. The Dow is down over 200 points today and ITRO is holding up well. You need to face the reality that most stocks are either over-priced or under-priced at any given moment and pinksheets stocks are an exaggeration of those extremes. ITRO has taken a long time to get into the hole that it has dug and it will take some time for people to see and trust the progress. When this finally happens the pendulum will swing the other way. It will take a few quarters of proof and if you "believe" it will happen then the current price is an opportunity. For your own health, stop trying to out guess how the market should value ITRO and look forward without rehashing the past. Know what you own and why you own it.